1 Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014
2 Scope of GMP GMP compliance is widely-accepted as the best way to conduct business, putting product quality first. GMP rules are a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
3 Scope of GMP We have to trust in the manufacturer and in the supply chain:
4 GMP history USA History begins in the USA when: 1938 Federal Food, Drug & Cosmetic (FD&C) Act: new drug premarketing safety studies, prohibition of false therapeutic claims, introduction of factory inspections 1963 First Drugs GMPs (28 FR 6385) after thalidomide tragedy: proof of efficacy, adverse events reporting to FDA, informed content for clinical studies 1978 Human & Veterinary Drugs GMP revision (21 CFR Parts 210 and 211) resulted from FDA Task Force studying GMPs
5 GMP history USA 1980s-1990s Publishing of a series of FDA guidance documents Some examples: 1983: Guide to the Inspection of Computerized Systems in Drug Processing 1987: Guideline on General Principles of Process Validation 1998: Draft Guidance for Industry: Investigating OOS Test Results for Pharmaceutical Production 1998: Draft Guidance for Industry Manufacture, Processing or Holding Active Pharmaceutical Ingredients
6 GMP history Rest of world Outside USA: 1963 Resolution World Health Assembly16.36 (on drug safety and monitoring) reaffirmed the need for early action in regard to adverse drug reactions 1965 European Union issued Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (where it is stated that marketing authorization is granted upon availability of physico-chemical, biological or microbiological tests, pharmacological and toxicological tests, clinical trials) 1968 Medicines Act 1968, an Act of Parliament of the United Kingdom, which governs the control of medicines for human use and for veterinary use, which includes the manufacture and supply of medicines.
7 GMP history Harmonization As there was adequate international agreement on the technical aspects of Good Manufacturing Practices (GMP) for Pharmaceutical Products and further harmonisation action through ICH was not needed, attention has focused on the need to formalise GMP requirements for the components of pharmaceutical products - both active and inactive. In February 1998, the ICH Steering Committee agreed that GMP for Active Pharmaceutical Ingredients (APIs) should be adopted as an ICH Topic. ICH Tripartite Guideline Q7 Good manufacturing practice guide for Active Pharmaceutical Ingredients (Finalised Guideline: November 2000)
8 GMP history Harmonization Implementation (step 5 of the harmonization process) occurred as follows: MHLW Japan: Adopted November 2001, PMSB/ELD Notification No FDA: Published in the Federal Register, 25 September 2001, Vol. 66, No. 186, p (replaced FDA s 1998 draft guidance)
9 GMP history Harmonization EU: Adopted by CPMP, November 2000, issued as CPMP/ICH/4106/00 and published in July 2001 as Annex 18 to the GMP Guide reflecting the EU s agreement to ICH Q7 and has been used by manufacturers and GMP inspectorates on a voluntary basis. In October 2005 Annex 18 has been replaced by the new guidance GMP Part II: Basic Requirements for Active Substances used as Starting Materials (Eudralex, volume 4). Last updating of GMP Part II has been published on August 2014 and is effective from September 1 st, 2014.
10 EU approach to GMP compliance - AIFA - Legal basis: Decree No. 219/2006, art. 53. Inspectors are spending more time looking at the equipment and the facility (e.g. cleaning procedures). Use of the concept of Qualified Person, who in many cases can be held personally liable for any deviations. Plant tour and congruence with Site Master File. Verification of DMF compliance with Master/Executed Batch Record. Verification of Manufacturing Licence and Products produced. Consequences of non-compliance, which may result in penal or civil charges.
11 EU approach to GMP compliance - EDQM - EDQM inspection programme is an integral part of Certification procedure and is elaborated in the context of the mandate given to EDQM by the European Commission in application of the Directives 2001/83/EC and 2001/82/EC as amended. It is aimed to check compliance with both GMP (Eudralex, Vol. 4, Part II) and the Certificate of Suitability (CEP) application (and any updates) at the manufacturing/distribution sites covered by CEPs. Every year, a programme of inspections is elaborated based on prioritisation, in accordance with the EU recommendations (trigger doc. EMA/INS/GMP/459921/ Compilation of Community Procedures on Inspections and Exchange of Information). Inspections are carried out by official inspectors from the competent authorities in the EU/EEA, or in countries which have a Mutual Recognition Agreement with EU in GMP sector, as well as EDQM inspectors having the same qualification.
12 EU approach to GMP compliance - EMA - The European Medicines Agency s Manufacturing and Quality Compliance Section coordinates GMP inspections of manufacturing sites connected to centrally authorised human and veterinary medicines, according to the Standard Operating Procedure Coordination of GMP/GDP inspections (document No. SOP/INSP/2048 effective from September 27, 2012). As manufacturers located within the EEA are under the direct supervision of regulatory authorities in Member States, the Agency does not specifically request inspections of manufacturers located in the EEA except when the need arises for a specific medicine, usually during the pre-authorisation phase of a centralised marketingauthorisation application. The majority of inspections requested by the Agency are in countries outside the EU ('third countries').
13 EU approach to GMP compliance - EMA - The Agency has conducted two pilot programs of inspections with international partners. One of this concerns APIs. Representatives from authorities in Europe, including EMA, five EU Member States (France, Germany, Ireland, Italy and UK) and EDQM conducted a joint initiative with the United States FDA and the Australian TGA on international GMP inspections of APIs manufacturers located outside the participating countries. Objectives of the initiative included sharing of information on inspection planning, policy and inspection reports and joint inspections. The programme began with a pilot, which ran from December 2008 until December During the pilot, the participants shared their surveillance lists and found 97 sites common to all three regions, resulting in the exchange of nearly 100 inspection reports and in nine joint inspections.
14 EU approach to GMP compliance - EMA - This led to increased levels of understanding between the agencies, and a greater number of inspections of value to more than one authority. An interim report on the pilot was published in October 2010 and the final report was published in August Based on the positive experience, the agencies have agreed to continue with their collaboration, taking into account the experiences and lessons learned during the pilot. This has paved the way for all EU Member States to participate actively in this collaboration. The project has contributed substantially to a better understanding of regional approaches to inspection and the building of mutual confidence.
15 EU approach to GMP compliance - EMA - From the experience gained so far, the following measures have been recommended in order to improve international collaboration for the benefit of public health: to include in a shared database an all extensive list of API manufacturers registered in the different participants countries in order to identify, all shared sites which should be subjected to regular work sharing but also identify other critical sites for example in terms of monopoly position, etc. EUDRA-GMDP database to consider the development and implementation amongst the participants of a common policy related to the re-inspection of shared sites located in third countries (frequency based on risk).
16 FDA approach to GMP compliance Investigators are focused on GMPs (deviation handling and failure investigation) and registration issues. Audit technique: document trail. Specific GMP topics: - Label reconciliation - Pre-numbered worksheets - Annual Product Review - Out of specification handling Consequences of non-compliance, which may result in criminal or civil charges.
17 Mutual Recognition Agreements (MRAs) Mutual Recognition Agreements are essential to avoid multiple inspections, which are becoming a major problem for manufacturers. MRAs can avoid: Costly re-analysis of imported products Have the potential to promote GMP harmonization Stumble points to such agreements include standards equivalence and national inspection system
18 Mutual Recognition Agreements (MRAs) Status of MRAs in place: Australia: Fully operational Canada: In operation, except for preapproval inspections and medicinal products derived from blood or blood plasma Israel: Operational with some exclusions Japan: Operational on 29 May with limited scope New Zealand: Fully operational Switzerland: Fully operational USA: Not in operation
19 Written Confirmation Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products introduces EU-wide rules for the importation of active substances: according to Article 46b(2) of Directive 2001/83/EC, active substances shall only be imported if, inter alia, accompanied by a written confirmation from the competent authority of the exporting third country which, as regards the plant manufacturing the exported active substance, confirms that the standards of good manufacturing practice and control of the plant are equivalent to those in the Union.
20 Written Confirmation The template for the written confirmation has been published in Part III of EudraLex, Volume 4. The core of the declaration is the following: THE ISSUING REGULATORY AUTHORITY HEREBY CONFIRMS THAT: The standards of good manufacturing practice (GMP) applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7); The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.6.
21 Written Confirmation Whenever an active substance manufacturing site is found not to comply with EU GMP for active substances following an inspection by a EU member state, a statement of non-compliance (NCS) is issued and entered in EudraGMDP. NCS are now publicly available and can be accessed through the "GMP" tab of the EudraGMDP database. A NCS issued by a EU Member State for a specific active substance manufacturing site normally results in measures taken by the relevant EU authorities to prevent the use across the EU of the active substance(s) produced in the site in question. A NCS therefore supersedes the corresponding written confirmation (if it exists) issued by the third country.
22 Written Confirmation Listing of third countries assessed or currently under assessment for equivalence of GMP system: Country Date of request Status, Date of publication in the Official Journal of the European Union Switzerland 4 April 2012 Adopted, Commission implementing Decision (OJ L 325, ) Israel 9 May 2012 Contacts ongoing. Australia 18 September 2012 Adopted, Commission implementing Decision (OJ L 113, ) Singapore 17 September 2012 No listing for the moment (the relevant Singapore legislation provides for a non-mandatory GMP certification scheme). Contacts ongoing. In the meantime, Singapore issues written confirmation. Brazil 4 October 2012 Equivalence assessment ongoing Japan 6 December 2012 Adopted, Commission implementing Decision (OJ L 152/52, ) United States 17 January 2013 Adopted, Commission Implementing Decision (OJ L 169/71, ) New Zealand 26 June 2013 Assessment ongoing
23 USP Verification Services U.S. Pharmacopoeia offers verification services for dietary supplement finished products, dietary ingredients, pharmaceutical ingredients, and excipients. Products and ingredients that meet all USP verification requirements including a GMP audit, product and ingredient testing, and manufacturing documentation review are awarded use of the distinctive USP Verified Marks. Participation is voluntary and available to manufacturers worldwide. USP's verification services draw upon experience setting federally recognized public standards of quality for medicines, dietary supplements, and foods. USP has been establishing standards since 1820, and, today USP standards are used in more than 140 countries.
24 USP Verification Services Key Elements of the Verification Programs
25 USP Verified Pharmaceutical Ingredients U.S. Pharmacopoeia offers a rigorous third-party verification program to help companies reach best practice quality management for drug substances used in the manufacture of drug products and demonstrate that their ingredients are of consistent high quality. USP experts provide participants with a good manufacturing practice (GMP) audit of manufacturing facilities and operations based on ICH Q7; a review of drug substance chemistry, manufacturing and controls (CMC) documentation; laboratory testing of drug substances for conformance to specifications; and ongoing change monitoring and surveillance.
26 USP Verified Pharmaceutical Ingredients Ingredients that meet USP s stringent requirements are awarded a Certificate of Standards Compliance and use of the USP Verified Pharmaceutical Ingredient Mark. The Mark can be used on the bulk label of each container of verified ingredients and on the accompanying certificate of analysis. The Mark provides assurance that the ingredient is manufactured in accordance with internationally accepted GMPs for pharmaceutical ingredients; meets label and certificate of analysis claims for identification, strength, purity, and quality; meets acceptable limits for impurities and contaminants; and is consistent in quality from batch to batch.
27 Conclusion Based on this brief excursus, we can say that regulatory approaches on GMP compliance have reached a good degree of harmonization, allowed by the great efforts carried out by all the regulatory bodies involved.
EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond 14 th International Conference of Drug Regulatory Authorities Pre-ICDRA Meeting Dr Susanne Keitel European Directorate
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medicinal products quality, safety and efficacy Brussels, IMPORTATION OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013) IMPORTATION OF ACTIVE SUBSTANCES
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
The European Pharmacopoeia and certificates of suitability (CEP) Your Logo Andrew McMath Ph.D. European Directorate for the Quality of Medicines (EDQM) Presented by: Andrew McMath Scientific Officer, EDQM
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community
1 1. Name of pharmacopoeia European Pharmacopoeia 36 Member states (Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
Medical Devices Notified Bodies and the CE certification Process for Medical Devices European Surgical Robotics Demonstration Day 27 th March 2014, Leuven, Belgium 1 Bart Mersseman Product Manager Medical
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
GMP and QMS Regulation in Japan Tomiko Tawaragi Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) August 2 nd, 2014 1 st Brazil-Japan Seminar GMP/QMS GMP : Good Manufacture Practice
The APIC Audit Programme Standardised Cost APIC-certified GMP Compliance A Third Party Audit Programme for API Manufactureres An Initiative of APIC in co-operation with CONCEPT HEIDELBERG A sector group
Global Good Manufacturing Practice A Comparability Study to Link Good Manufacturing Practice Standards for World Wide Compliance Within the Cellular Therapy Industry Presented by Rosemarie Bell 24 April
European Medicines Agency CHMP/QWP/297/97 Rev 1 corr EMEA/CVMP/1069/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON SUMMARY
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing Katherine L. Ulman and Dr. Patricia Rafidison Dow Corning Healthcare About the Authors
Marketing Authorisation Variations - Supplementary Guidance The following includes specific guidance in relation to some common scenarios which are presented as variations and as appropriate these should
22 November 2012 EMA/590745/2012 Patient Health Protection Reflection paper on medicinal product supply shortages caused by manufacturing/good Manufacturing Practice Compliance problems 1. Introduction
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
The 9 th Edition of the Ph. Eur. & current hot topics Japanese Pharmacopoiea 130 th Annivsersary Symposium 15 th September 2016 Toyko, Japan Dr Susanne KEITEL Director European Directorate for the Quality
INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 27 June 2013 EMA/385898/2013 Rev 16 Compliance and Inspection Compilation of Community
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
STATUTORY INSTRUMENTS 2002 No. 618 CONSUMER PROTECTION The Medical Devices Regulations 2002 Made - - - - - 20th May 2002 Laid before Parliament 21st May 2002 Coming into force - - 13th June 2002 ARRANGEMENT
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group firstname.lastname@example.org Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
Integrating Good Manufacturing Practices During the Transition from Clinical Trials to Commercial Manufacturing By Mark Zemler W H I T E P A P E R Executive Summary In support of our customers, this whitepaper
CE Marking: Your Key to Entering the European Market N. Gerard Zapiain U.S. Department of Commerce International Trade Administration Office of Microelectronics, Medical Equipment and Instrumentation I.
Supply Chain Challenges and Risk Management Presented by Steve Williams Director SeerPharma P/L 21 st April 2009 PDA April 09 SW 1 Supply Chain - Some Useful Guidance cgmp Annex 8 cgmp Chapter 7 ICH Q7
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
GMP Rules and Guidelines in 2013 for Computer System Validation / Computerises Systems / Electronic Records and Signatures/ IT Infrastructure and Application Compliance: What is the correct title of this
Regulatory Reform: Are we heading in the right direction? Trisha Garrett, Assistant Secretary, Complementary and OTC Medicines Branch 11 November 2015 Where are we going? 2 Update TGA Update 1. TGA restructure
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
23 October 2014 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft agreed by Biosimilar Medicinal Products Working Party and Biologics Working Party March 2013 Adopted by CHMP
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
Cosmetic products in China Imported cosmetics need pre-market approval before entering China All cosmetics imported into China are required to obtain pre-market approval or notification from the Chinese
Cosmetics Regulation in the United States and the European Union: Different Pathways to the Same Result By Richard Kingham and Lucas E. Beirne Introduction It is sometimes suggested that cosmetic products
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
2014 ISCT-GRP Workshop Session I Welcome to PIC/S: Regulatory implications of migration Ellen, Ying-Hua Chen Section Chief / GMP Inspector Food and Drug Administration Ministry of Health and Welfare Taiwan
BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 EudraLex The Rules Governing Medicinal Products in
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064587 EudraLex The Rules Governing Medicinal Products
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
L 218/82 EN Official Journal of the European Union 13.8.2008 DECISIONS ADOPTED JOINTLY BY THE EUROPEAN PARLIAMENT AND THE COUNCIL DECISION No 768/2008/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of
The Formalized Risk Assessment for Excipients A Practical Approach Frithjof Holtz, IPEC Europe Vice-Chair, Merck Presentation Overview Regulatory Background EU FMD and Formalized Risk Assessment Proposal
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the
Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
RAPS ONLINE UNIVERSITY Practical education and training for business success. For regulatory professionals, there is only one name to know and trust for online education and training RAPS Online University.
TEXTUAL PROPOSAL SANITARY AND PHYTOSANITARY MEASURES (SPS) Article 1 Scope and coverage This Chapter applies to all SPS measures that may, directly or indirectly, affect trade between the Parties. This
GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES A WHITE PAPER ON THE REQUIREMENTS, REGULATIONS AND OPPORTUNITIES CONTAINED IN EC DIRECTIVE 98/79/EC AND A BRIEF COMPARISON
GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors This course is a distance-learning program that will culminate in a Graduate
NSF Dietary Supplements Complete Service Offering Experts in supplement auditing, testing and training www.nsf.org About Us NSF International is the Public Health and Safety Organization, offering public